Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First or Second Line Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04050449
What this trial is testing

Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

Who this might be right for
HIV-1-infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 1,339
Large-scale testing (Phase 3)Study completedNCT02890784
What this trial is testing

Dasatinib Holiday for Improved Tolerability

Who this might be right for
Myeloid Leukemia, Chronic
University of Jena 291
Testing effectiveness (Phase 2)Active Not RecruitingNCT04884282
What this trial is testing

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Fondazione Ricerca Traslazionale 105
Testing effectiveness (Phase 2)Ended earlyNCT03695250
What this trial is testing

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Who this might be right for
Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8+5 more
Edward Kim 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45
Large-scale testing (Phase 3)Study completedNCT01160211
What this trial is testing

Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 369
Testing effectiveness (Phase 2)Study completedNCT01482299
What this trial is testing

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Who this might be right for
Stomach Neoplasm
Asan Medical Center 45
Testing effectiveness (Phase 2)Ended earlyNCT02461134
What this trial is testing

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Who this might be right for
Chronic Graft Versus Host Disease
Actelion 1
Large-scale testing (Phase 3)Study completedNCT01878422
What this trial is testing

Sequential Treatment Strategy for Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 376
Testing effectiveness (Phase 2)Study completedNCT00709761
What this trial is testing

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)UnknownNCT02501551
What this trial is testing

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Who this might be right for
Melanoma
Yonsei University 36
Early research (Phase 1)Study completedNCT00661739
What this trial is testing

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GBG Forschungs GmbH 38
Not applicableWithdrawnNCT03161613
What this trial is testing

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Who this might be right for
Multiple Indications Cancer
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Study completedNCT00111839
What this trial is testing

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

Who this might be right for
Lung CancerNon Small Cell Lung Carcinoma
EMD Serono 150
Testing effectiveness (Phase 2)Study completedNCT03499899
What this trial is testing

Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Novartis Pharmaceuticals 88
Not applicableStudy completedNCT01664533
What this trial is testing

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 57
Post-approval studies (Phase 4)Looking for participantsNCT07600164
What this trial is testing

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Who this might be right for
HER2 + Breast CancerAdvanced Breast Cancer
Peking University People's Hospital 500
Testing effectiveness (Phase 2)Study completedNCT01322152
What this trial is testing

Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Fudan University 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT05865132
What this trial is testing

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Who this might be right for
Esophagus Squamous Cell Carcinoma
AIPING ZHOU 30
Next Page
60